Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue
+9.30%
EPS
+25.9%
Free cash flow
+20.4%
Total debt
+21.0%

Quarter to September 2026, against a year earlier

119.68 4.43 −3.57%
Market cap
$5.7B
P/E
54.5×
Fwd P/E
30.2×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17
Piotroski F-Score
6 6 7 8 5 5 8 7 7 5
P/E ratio
27.76 19.03 37.03 36.78 75.26 71.16 66.00 85.48 83.91 0.00
Altman Z-Score
2.21 2.41 3.43 3.63 2.78 4.16 5.91 5.93 6.09 3.79
P/S ratio
1.99 2.35 3.28 3.60 3.25 6.46 5.11 4.78 4.21 2.36
Altman Z″-Score (non-manufacturers)
2.85 2.56 3.26 3.49 2.46 2.91 3.36 3.76 3.36 3.80
P/FCF ratio
10.16 19.30 29.56 50.42 41.49 76.47 40.02 107.23 25.67 24.19
Beneish M-Score
(2.81) (2.64) (2.42) (2.73) (2.71) (2.57) (2.92) (2.73) (3.19) (3.20)
P/Operating CF
37.48 27.44 67.09 52.79 47.42 3,637.28 108.86 224.11 66.06 60.45
P/B ratio
3.34 3.90 4.48 5.14 4.31 7.69 8.60 6.93 5.06 2.83
EV/Sales
2.72 2.80 3.76 4.00 3.55 7.04 5.28 4.94 4.08 2.49
EV/EBITDA
13.25 10.82 18.53 18.74 19.39 35.08 24.37 24.76 25.35 31.33
EV/FCF
13.88 23.01 33.82 56.06 45.35 83.24 41.35 110.78 24.85 25.51
Current Ratio
2.95 1.62 2.56 3.06 1.71 2.74 2.20 2.44 1.35 2.42
Net Debt/EBITDA
3.55 1.74 2.33 1.88 1.65 2.85 0.79 0.79 (0.83) 1.62
Debt/Equity
1.53 1.12 0.83 0.92 0.75 0.94 0.52 0.48 0.08 0.34
ROE
12.03% 18.83% 13.22% 14.72% 5.86% 12.05% 12.20% 7.75% 6.11% (3.60%)
ROA
4.02% 7.22% 5.69% 6.08% 2.36% 5.15% 6.02% 4.38% 3.68% (2.05%)
ROIC
5.53% 9.66% 6.53% 7.57% 4.81% 4.56% 8.55% 6.36% 5.56% (1.42%)
Return on Tangible Assets
11.34% 26.16% 15.07% 13.92% 7.58% 12.08% 13.14% 8.04% 9.72% (4.22%)
Average Days of Receivables
59.33 54.36 57.60 55.95 58.57 53.49 61.00 69.80 61.06 62.89
Earnings Yield
3.60% 5.26% 2.70% 2.72% 1.33% 1.41% 1.52% 1.17% 1.19% (1.23%)
Free Cash Flow Yield
9.85% 5.18% 3.38% 1.98% 2.41% 1.31% 2.50% 0.93% 3.90% 4.13%
Free Cash Flow per Share
5.55 3.29 2.87 1.64 1.52 1.45 2.49 0.84 2.81 1.68
Book value per Share
16.88 16.31 18.93 16.11 14.68 14.43 11.58 12.96 14.26 14.35
Free Cash Flow
261.82 165.70 145.44 83.34 77.78 73.58 126.23 43.13 148.31 86.43
EV/EBIT
23.18 17.19 29.83 29.94 43.68 68.25 50.51 57.19 65.64 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026